PROCLAIM Consortium

Overview

The widespread use of the atypical antipsychotic, clozapine, has been limited due to considerable risks of rare but potentially fatal adverse side effects. Among these adverse effects, cardiac side effects such as myocarditis are under-appreciated despite their association with increased risk of death. Unfortunately, our ability to identify those at greatest risk for clozapine-associated cardiac side effects is poor.

In response to this gap in knowledge, we have established the Pharmacogenetics of Clozapine-Induced Myocarditis (PROCLAIM) Consortium. The PROCLAIM Consortium is uniting investigators around the world to uncover genomic markers that could be used preemptively by clinicians to identify those patients at highest risk for myocarditis from clozapine therapy and identify the mechanism by which clozapine induces myocardial inflammation and damage.

We invite all clinicians and/or investigators who have cared for and/or studied individuals that have developed myocarditis following clozapine exposure to join the PROCLAIM Consortium. We are particularly interested in members who can contribute samples and/or genomic data that would enable pooled analyses to be performed. Please contact us if you are interested in becoming a site.

History

The PROCLAIM Consortium was initiated in 2017 by Dr Chad Bousman and Prof Christos Pantelis at the University of Melbourne. The first nine participants were recruited from the Adult Mental Health Rehabilitation Unit at Sunshine Hospital in Melbourne, Australia. In late 2017, Dr Bousman and the PROCLAIM Consortium relocated to the University of Calgary, maintaining the University of Melbourne as a study site. Currently there are 15 sites covering Australia, Canada, Turkey and the US (see below for site details and investigators affiliated with the study).

Funding

University of Melbourne Establishment Grant (2017, Bousman)

University of Calgary, Cumming School of Medicine (2017-2019, Bousman)

Study Aims

1. Identify clinical factors associated with clozapine-induced myocarditis.

2. Discover genomic markers that could be developed into a clinical tool to identify patients at high risk for myocarditis caused by clozapine.

3. Understand how clozapine induces myocardial inflammation and damage and ultimately identify a modifiable mechanism.


PROCLAIM Consortium Sites

If your hospital/centre/clinic would like to join the PROCLAIM Consortium please contact us!

Study Team

Principal Investigator:

Chad Bousman, MPH, PhD

University of Calgary


Co-Investigators:

University of Calgary

Steven Greenway, MSC, MD, FRCPC

Quan Long, PhD

Rory Sellmer, BPE, MD, FRCPC

David Crockford, MD, FRCPC, DABPN, FAPA, FCPA

Maja Tarailo-Graovac, BSc, PhD


University of Alberta

Katherine Aitchison, BM BCh, PhD, MRCPsych


University of Toronto, Centre for Addictions & Mental Health

Gary Remington, MD, PhD


William Osler Health System

Shailesh Nadkarni, MBBS, MHSA

Amlan Das, MD

Charles Ohene-Darkoh, MD


University of British Columbia

Robert Stowe, MD, ABPN, FRCPC


University of Saskatchewan

Rohit Lodhi, PhD, FRANZCP, MRCPsych, MD Psych, D.P.M


University of Melbourne

Christos Pantelis, MBBS, MRCPsych, MD, FRANZCP

Naveen Thomas, MBBS

Mahesh Jayaram, MBBS, DPM, MMedSc


Monash University

Kathlyn Ronaldson, BSc, MSc, DPhil, MPH

John McNeil, MBBS, MSc, PhD, FRACP, FAFPHM

Paul Lacaze, PhD


University of New South Wales, Neuroscience Research Australia

Cynthia Shannon Weickert, BA, Mphil, PhD


University of Queensland

Dan Siskind, MD, PhD

Karl Winckel, BPharm


The University of Newcastle

Murray Cairns, PhD


James Cook University

Tahnee L Bridson, MBBS BMedSc


Harvard University

Kevin J Li, MD

Lynn DeLisi, MD

Ronald Gurerra, MD

Jerry Fleming, MPH


University of Iowa

Jess Fiedorowicz, M.D., Ph.D.

Mark Niciu, MD, PhD


Hacettepe University (Turkey)

A. Elif Anil Yagcioglu, MD